153 related articles for article (PubMed ID: 37730754)
1. Sequential genomic analysis using a multisample/multiplatform approach to better define rhabdomyosarcoma progression and relapse.
de Traux de Wardin H; Dermawan JK; Merlin MS; Wexler LH; Orbach D; Vanoli F; Schleiermacher G; Geoerger B; Ballet S; Guillemot D; Frouin E; Cyrille S; Delattre O; Pierron G; Antonescu CR
NPJ Precis Oncol; 2023 Sep; 7(1):96. PubMed ID: 37730754
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Abbou S; Klega K; Tsuji J; Tanhaemami M; Hall D; Barkauskas DA; Krailo MD; Cibulskis C; Nag A; Thorner AR; Pollock S; Imamovic-Tuco A; Shern JF; DuBois SG; Venkatramani R; Hawkins DS; Crompton BD
J Clin Oncol; 2023 May; 41(13):2382-2393. PubMed ID: 36724417
[TBL] [Abstract][Full Text] [Related]
3. Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study.
Ruhen O; Lak NSM; Stutterheim J; Danielli SG; Chicard M; Iddir Y; Saint-Charles A; Di Paolo V; Tombolan L; Gatz SA; Aladowicz E; Proszek P; Jamal S; Stankunaite R; Hughes D; Carter P; Izquierdo E; Wasti A; Chisholm JC; George SL; Pace E; Chesler L; Aerts I; Pierron G; Zaidi S; Delattre O; Surdez D; Kelsey A; Hubank M; Bonvini P; Bisogno G; Di Giannatale A; Schleiermacher G; Schäfer BW; Tytgat GAM; Shipley J
JCO Precis Oncol; 2022 Oct; 6():e2100534. PubMed ID: 36265118
[TBL] [Abstract][Full Text] [Related]
4. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
[TBL] [Abstract][Full Text] [Related]
5. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG
Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182
[TBL] [Abstract][Full Text] [Related]
6. Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease.
Hemming ML; Klega KS; Rhoades J; Ha G; Acker KE; Andersen JL; Thai E; Nag A; Thorner AR; Raut CP; George S; Crompton BD
JCO Precis Oncol; 2019; 2019():. PubMed ID: 30793095
[TBL] [Abstract][Full Text] [Related]
7. Genetic heterogeneity in rhabdomyosarcoma revealed by SNP array analysis.
Walther C; Mayrhofer M; Nilsson J; Hofvander J; Jonson T; Mandahl N; Øra I; Gisselsson D; Mertens F
Genes Chromosomes Cancer; 2016 Jan; 55(1):3-15. PubMed ID: 26482321
[TBL] [Abstract][Full Text] [Related]
8. Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial.
Sabatier R; Garnier S; Guille A; Carbuccia N; Pakradouni J; Adelaide J; Provansal M; Cappiello M; Rousseau F; Chaffanet M; Birnbaum D; Mamessier E; Gonçalves A; Bertucci F
Front Oncol; 2022; 12():946257. PubMed ID: 35965534
[TBL] [Abstract][Full Text] [Related]
9. Spermine oxidase induces DNA damage and sensitizes fusion negative rhabdomyosarcoma cells to irradiation.
Perrone C; Pomella S; Cassandri M; Pezzella M; Giuliani S; Gasperi T; Porrazzo A; Alisi A; Pastore A; Codenotti S; Fanzani A; Barillari G; Conti LA; De Angelis B; Quintarelli C; Mariottini P; Locatelli F; Marampon F; Rota R; Cervelli M
Front Cell Dev Biol; 2023; 11():1061570. PubMed ID: 36755974
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic role of HMGA2 in fusion-negative rhabdomyosarcoma cells.
Ouchi K; Miyachi M; Yagyu S; Kikuchi K; Kuwahara Y; Tsuchiya K; Iehara T; Hosoi H
Cancer Cell Int; 2020; 20():192. PubMed ID: 32489328
[TBL] [Abstract][Full Text] [Related]
11. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
12. Loss of Chromosome 3q Is a Prognostic Marker in Fusion-Negative Rhabdomyosarcoma.
Dehner CA; Bell RC; Cao Y; He K; Chrisinger JSA; Armstrong AE; Yohe M; Shern J; Hirbe AC
JCO Precis Oncol; 2023 Sep; 7():e2300037. PubMed ID: 37738543
[TBL] [Abstract][Full Text] [Related]
13. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
14. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma.
Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P
Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014
[TBL] [Abstract][Full Text] [Related]
15. Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice.
Imperial R; Nazer M; Ahmed Z; Kam AE; Pluard TJ; Bahaj W; Levy M; Kuzel TM; Hayden DM; Pappas SG; Subramanian J; Masood A
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31546879
[TBL] [Abstract][Full Text] [Related]
16. Identify potential driver genes for PAX-FOXO1 fusion-negative rhabdomyosarcoma through frequent gene co-expression network mining.
Zhan X; Liu Y; Jannu AJ; Huang S; Ye B; Wei W; Pandya PH; Ye X; Pollok KE; Renbarger JL; Huang K; Zhang J
Front Oncol; 2023; 13():1080989. PubMed ID: 36793601
[TBL] [Abstract][Full Text] [Related]
17. Whole-genome informed circulating tumor DNA analysis by multiplex digital PCR for disease monitoring in B-cell lymphomas: a proof-of-concept study.
Haider Z; Wästerlid T; Spångberg LD; Rabbani L; Jylhä C; Thorvaldsdottir B; Skaftason A; Awier HN; Krstic A; Gellerbring A; Lyander A; Hägglund M; Jeggari A; Rassidakis G; Sonnevi K; Sander B; Rosenquist R; Tham E; Smedby KE
Front Oncol; 2023; 13():1176698. PubMed ID: 37333831
[TBL] [Abstract][Full Text] [Related]
18. Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.
Remon J; Swalduz A; Planchard D; Ortiz-Cuaran S; Mezquita L; Lacroix L; Jovelet C; Rouleau E; Leonce C; De Kievit F; Morris C; Jones G; Mercier K; Howarth K; Green E; Pérol M; Saintigny P; Besse B
PLoS One; 2020; 15(6):e0234302. PubMed ID: 32525942
[TBL] [Abstract][Full Text] [Related]
19. Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma.
Chicard M; Colmet-Daage L; Clement N; Danzon A; Bohec M; Bernard V; Baulande S; Bellini A; Deveau P; Pierron G; Lapouble E; Janoueix-Lerosey I; Peuchmaur M; Corradini N; Defachelles AS; Valteau-Couanet D; Michon J; Combaret V; Delattre O; Schleiermacher G
Clin Cancer Res; 2018 Feb; 24(4):939-949. PubMed ID: 29191970
[No Abstract] [Full Text] [Related]
20. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
